Cargando…

Elexacaftor Mediates the Rescue of F508del CFTR Functional Expression Interacting with MSD2

Cystic fibrosis (CF) is one of the most frequent lethal autosomal recessive diseases affecting the Caucasian population. It is caused by loss of function variants of the cystic fibrosis transmembrane conductance regulator (CFTR), a membrane protein located on the apical side of epithelial cells. The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bongiorno, Roberta, Ludovico, Alessandra, Moran, Oscar, Baroni, Debora
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10454486/ https://www.ncbi.nlm.nih.gov/pubmed/37629017 http://dx.doi.org/10.3390/ijms241612838

Ejemplares similares

NBD2 Is Required for the Rescue of Mutant F508del CFTR by a Thiazole-Based Molecule: A Class II Corrector for the Multi-Drug Therapy of Cystic Fibrosis
por: Brandas, Chiara, et al.
Publicado: (2021)

Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors
por: Amico, Giulia, et al.
Publicado: (2019)

Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination
por: Veit, Guido, et al.
Publicado: (2020)

Extracellular phosphate enhances the function of F508del-CFTR rescued by CFTR correctors
por: Saint-Criq, Vinciane, et al.
Publicado: (2021)

Correctors modify the bicarbonate permeability of F508del-CFTR
por: Fiore, Michele, et al.
Publicado: (2020)

Functional Rescue of F508del-CFTR Using Small Molecule Correctors
por: Molinski, Steven, et al.
Publicado: (2012)

Calpain Inhibition Promotes the Rescue of F(508)del-CFTR in PBMC from Cystic Fibrosis Patients
por: Averna, Monica, et al.
Publicado: (2013)

Elexacaftor/tezacaftor/ivacaftor as rescue therapy in a patient with the cystic fibrosis genotype F508DEL/G1244E
por: Salvatore, Donatello, et al.
Publicado: (2021)

The CFTR Amplifier Nesolicaftor Rescues TGF-β1 Inhibition of Modulator-Corrected F508del CFTR Function
por: Bengtson, Charles, et al.
Publicado: (2022)

Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment
por: Capurro, Valeria, et al.
Publicado: (2021)

The L467F-F508del Complex Allele Hampers Pharmacological Rescue of Mutant CFTR by Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients: The Value of the Ex Vivo Nasal Epithelial Model to Address Non-Responders to CFTR-Modulating Drugs
por: Sondo, Elvira, et al.
Publicado: (2022)

ΔF508 CFTR interactome remodeling promotes rescue of Cystic Fibrosis
por: Pankow, Sandra, et al.
Publicado: (2015)

Full Rescue of F508del-CFTR Processing and Function by CFTR Modulators Can Be Achieved by Removal of Two Regulatory Regions
por: Uliyakina, Inna, et al.
Publicado: (2020)

Elexacaftor–Tezacaftor–Ivacaftor Therapy for Cystic Fibrosis Patients with The F508del/Unknown Genotype
por: Comegna, Marika, et al.
Publicado: (2021)

Analysis of multiple gene co-expression networks to discover interactions favoring CFTR biogenesis and ΔF508-CFTR rescue
por: Strub, Matthew D., et al.
Publicado: (2021)

Ouabain Mimics Low Temperature Rescue of F508del-CFTR in Cystic Fibrosis Epithelial Cells
por: Zhang, Donglei, et al.
Publicado: (2012)

Rescue of Murine F508del CFTR Activity in Native Intestine by Low Temperature and Proteasome Inhibitors
por: Wilke, Martina, et al.
Publicado: (2012)

Phosphorylation of the Chaperone-Like HspB5 Rescues Trafficking and Function of F508del-CFTR
por: Degrugillier, Fanny, et al.
Publicado: (2020)

SFPQ rescues F508del-CFTR expression and function in cystic fibrosis bronchial epithelial cells
por: Kumar, Parameet, et al.
Publicado: (2021)

KDM2A and KDM3B as Potential Targets for the Rescue of F508del-CFTR
por: D’Amore, Claudio, et al.
Publicado: (2022)

Characterization of Nasal Potential Difference in cftr Knockout and F508del-CFTR Mice
por: Saussereau, Emilie Lyne, et al.
Publicado: (2013)

Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator
por: Laselva, Onofrio, et al.
Publicado: (2021)

Targeting the E1 ubiquitin-activating enzyme (UBA1) improves elexacaftor/tezacaftor/ivacaftor efficacy towards F508del and rare misfolded CFTR mutants
por: Borgo, Christian, et al.
Publicado: (2022)

Molecular Docking and QSAR Studies as Computational Tools Exploring the Rescue Ability of F508del CFTR Correctors
por: Righetti, Giada, et al.
Publicado: (2020)

Production of CFTR-ΔF508 Rabbits
por: Yang, Dongshan, et al.
Publicado: (2021)

Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation
por: Stefano, Daniela De, et al.
Publicado: (2014)

Structural Comparative Modeling of Multi-Domain F508del CFTR
por: McDonald, Eli Fritz, et al.
Publicado: (2022)

Recovery of ΔF508-CFTR Function by Citrate
por: Borkenhagen, Beatrice, et al.
Publicado: (2022)

The Primary Folding Defect and Rescue of ΔF508 CFTR Emerge during Translation of the Mutant Domain
por: Hoelen, Hanneke, et al.
Publicado: (2010)

Unravelling druggable signalling networks that control F508del-CFTR proteostasis
por: Hegde, Ramanath Narayana, et al.
Publicado: (2015)

Manipulating proteostasis to repair the F508del-CFTR defect in cystic fibrosis
por: Esposito, Speranza, et al.
Publicado: (2016)

An unexpected effect of TNF-α on F508del-CFTR maturation and function
por: Bitam, Sara, et al.
Publicado: (2015)

Defective Fluid Secretion from Submucosal Glands of Nasal Turbinates from CFTR(-/-) and CFTR(ΔF508/ΔF508) Pigs
por: Cho, Hyung-Ju, et al.
Publicado: (2011)

L1077P CFTR pathogenic variant function rescue by Elexacaftor–Tezacaftor–Ivacaftor in cystic fibrosis patient-derived air–liquid interface (ALI) cultures and organoids: in vitro guided personalized therapy of non-F508del patients
por: Lo Cicero, Stefania, et al.
Publicado: (2023)

Targeting protein–protein interactions to rescue Δf508-cftr: a novel corrector approach to treat cystic fibrosis
por: Devesa, Isabel, et al.
Publicado: (2013)

Molecular Structures Reveal Synergistic Rescue of Δ508 CFTR by Trikafta Modulators
por: Fiedorczuk, Karol, et al.
Publicado: (2022)

Correction to: L1077P CFTR pathogenic variant function rescue by Elexacaftor–Tezacaftor–Ivacaftor in cystic fbrosis patient-derived air–liquid interface (ALI) cultures and organoids: in vitro guided personalized therapy of non-F508del patients
por: Lo Cicero, Stefania, et al.
Publicado: (2023)

Virtual Drug Repositioning as a Tool to Identify Natural Small Molecules That Synergize with Lumacaftor in F508del-CFTR Binding and Rescuing
por: Fossa, Paola, et al.
Publicado: (2022)

Targeting DNAJB9, a novel ER luminal co-chaperone, to rescue ΔF508-CFTR
por: Huang, Yunjie, et al.
Publicado: (2019)

Integrative chemogenomic analysis identifies small molecules that partially rescue ΔF508‐CFTR for cystic fibrosis
por: Hodos, Rachel A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vnaiuk4oab6ftc3l8dbve729io